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Abstract
Background: To assess the quality of sweat test (ST) based on the proportion of sweat sodium and sweat chloride
as diagnostic parameter of cystic fibrosis (CF).
Methods: A retrospective study of 5,721 sweat samples and subsequent descriptive analysis were carried out. The
test was considered “of good quality” (correct) when: (i) sweat chloride was lower than 60 mEq/L, and sweat
sodium was higher than sweat chloride; (ii) sweat chloride was higher than 60 mEq/L, and sweat sodium was lower
than sweat chloride.
Results: The study included 5,692/5,721 sweat samples of ST which had been requested due to clinical
presentations compatible with CF and/or neonatal screenings with altered immunoreactive trypsinogen values.
Considering the proportion of sweat sodium and sweat chloride as ST quality parameter, the test was performed
correctly in 5,023/5,692 (88.2 %) sweat samples. The sweat chloride test results were grouped into four reference
ranges for chloride (i) chloride < 30 mEq/L: 3,651/5,692 (64.1 %); (ii) chloride ≥ 30 mEq/L to < 40 mEq/L: 652/5,692
(11.5 %); (iii) ≥ 40 mEq/L to < 60 mEq/L: 673/5,692 (11.8 %); (iv) ≥ 60 mEq/L: 716/5,692 (12.6 %). In the comparative
analysis, there was no association between ST quality and: (i) symptoms to indicate a ST [respiratory (p = 0.084),
digestive (p = 0.753), nutritional (p = 0.824), and others (p = 0.136)], (ii) sweat weight (p = 0.416). However, there was
a positive association with: (i) gender, (ii) results of ST (p < 0.001), (iii) chloride/sodium ratio (p < 0.001), (iv) subject’s
age at the time of ST [grouped according to category (p < 0.001) and numerical order (p < 0.001)]. For the subset of
169 patients with CF and two CFTR mutations Class I, II and/or III, in comparative analysis, there was a positive
association with: (i) sweat chloride/sodium ratio (p < 0.001), (ii) sweat chloride values (p = 0.047), (iii) subject’s age at
the time of the ST grouped by numerical order (p = 0.001).
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Conclusions: Considering that the quality of ST can be assessed by levels of sweat sodium and sweat chloride, an
increasing number of low-quality tests could be observed in our sweat samples. The quality of the test was
associated with important factors, such as gender, CF diagnosis, and subjects’ age.
Keywords: Cystic fibrosis, Diagnosis, Electrolytes, Sweat
Background
The sweat test (ST) is considered the gold standard for
the diagnosis of cystic fibrosis (CF) [1]. Around half a cen-
tury has passed since its description; however, questions
remain about its reproducibility and reliability, especially
in cases of borderline sweat results [2]. There are only a
few quality parameters to perform ST. In addition, the role
of sweat sodium as quality marker for ST is unknown.
Increased chloride values observed in ST are due to
mutations in the CFTR gene (Cystic Fibrosis Transmem-
brane Conductance Regulator), which encodes a protein
with the same name [3]. A conclusive diagnosis of CF
can be made with the identification of two mutations in
the CFTR gene [4, 5]. It is not always possible to con-
duct genetic tests and perform complete CFTR gene
sequencing for all patients, due to high costs and/or
technical limitations. And yet, ST has been widely used
as a tool for the diagnosis of CF for over 50 years.
Although ST has high sensitivity and specificity, it may
produce inconsistent results. Analysis of ST alone may
be insufficient to diagnose CF. Therefore; additional
tests should be performed, such as nasal potential differ-
ence measurement, assessment of CFTR function in rec-
tal biopsies, and evaporimetry [6–9]. Patients with CF
usually have low sodium conductance, and consequently,
elevated sodium concentration in sweat. This is because
the activity of the epithelial sodium channel depends on
the activity of the CFTR protein [10]. In CF diagnosis,
sodium has a poor discriminatory power in comparison
with chloride, even with an existing correlation between
their levels in sweat [1, 11, 12]. Current protocols do not
recommend the use of concentrations of sweat sodium
as a diagnostic parameter for CF and/or as a quality
marker to perform exams [12]. Although not used for
CF diagnosis, concentrations of sweat sodium are analyzed
by some laboratories, and used as an internal quality con-
trol procedure, since concentrations of chloride and
sodium tend to be similar [1, 2, 11]. The use of chloride/
sodium ratio has been proposed in order to screen pa-
tients with CF and borderline values in the ST. However,
there is no consensus on this quality parameter [2].
This study aimed to verify the quality of ST based on
the levels of sweat sodium and sweat chloride measured
in ST of subjects with and without CF, performed in a
referral center for a period of approximately 30 years
with the same sweat dosage method.
Methods
A retrospective study of 5,721 sweat samples and ST de-
scriptive analysis were carried out. The ST was considered
“of good quality” (correct) when: (i) sweat chloride was
lower than 60 mEq/L, and sweat sodium was higher than
sweat chloride in subjects without CF; (ii) sweat chloride
was higher than 60 mEq/L, and sweat sodium was lower
than sweat chloride in patients with CF (Fig. 1).
The concentrations of chloride and sodium in sweat
were determined by chloridrometry and flame photom-
etry, respectively. The collection of sweat was performed
by the classical Gibson & Cooke method [13].
The study was approved by the Ethics Committee
from University of Campinas (Unicamp) (# 474326). The
variables were collected from records of ST performed
in the laboratories of the center for Gastroenterology
Services and Pediatric Gastroenterology at the University
Hospital of the Unicamp.
The patients’ medical records included: name, age at
time of the examination, gender, medical record number,
indications for ST (pulmonary, digestive, nutritional
and/or others), family history of CF, weight of collected
sweat sample, concentrations of sweat chloride and
sweat sodium, and the chloride/sodium ratio in the
sweat samples. Tests with sweat weight lower than
75 mg were excluded.
Patients were grouped into three categories according to
age: (i) birth to < six months; (ii) ≥ 6 months to <18 years;
(iii) ≥ 18 years [2]. The concentration of sweat chloride
was used to group the sweat samples according to the CF
diagnosis, as follows: (i) chloride < than 30 mEq/L; (ii)
chloride ≥ 30 mEq/L to < 40 mEq/L; (iii) chloride ≥
40 mEq/L to < 60 mEq/L; (iv) ≥ 60 mEq/L (positive
test for CF) [14].
All test ordered for the same patient were analyzed,
even when a patient had undergone more than one test.
The study approached ST and not the result of the
prevalence of CF in the samples.
For a subset of 169 patients with CF, the CFTR muta-
tion screening was positive for two CFTR mutation Class
I, II and/or III. The samples with two CFTR mutation
Class I, II and/or III were analyzed individually. Muta-
tions of CFTR were analyzed by polymerase chain reac-
tion (PCR) (F508del) followed by enzymatic digestion
(G542X, R1162X, R553X, G551D and N1303K) – [PCR/
restriction fragment length polymorphism (RFLP)].
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Other mutations in the CFTR gene could be identified
by sequencing or use of the SALSA MLPA method
(Multiplex Ligation-dependent Probe Amplification) Kit
P091-C1 CFTR-MRC-Holland S4X, 2183A > G, 1717-
G > A, I618T with MegaBace1000® (GE Healthcare
Biosciences, Pittsburgh, USA) and ABI 3500 (Applied
Biosystems - Thermo Fisher Scientific, São Paulo/SP,
Brazil).
Descriptive statistics including numbers of observa-
tions, means, standard deviations, medians, minimums
and maximums were used to summarize continuous var-
iables. Confidence intervals (95 %) were calculated for
proportions. Categorical data was presented as tables of
frequency counts and associated percentages.
Statistical analysis was performed using SPSS software
(Statistical Package for Social Sciences) version 22.0
(SPSS Inc., Chicago, IL, USA) [15]. The comparison be-
tween variables with categorical distribution was carried
out by Test χ2 (Pearson and Likelihood ratio) and Fisher’s
exact test, depending on the data distribution. For the ana-
lysis of variables with numerical distribution, Fisher’s exact
test and one-way analysis of variance were used. Non-
parametric statistical test, such as Mann-Whitney and
Kruskal-Wallis, were applied when necessary. The graph-
ics and identification of difference between the groups ob-
tained by Kruskal-Wallis test were performed in MedCalc®
for Windows, version 16.1 (MedCalc® Software, Ostend,
Belgium). α = 0.05 was set for all analyses. The GPower
software version 3.1.9.2 (Moorenstraße, Düsseldorf,
Germany) [16, 17] was used to calculate the power of the
sample adopting power value above 80 %.
Results
The study included 5,721 sweat samples of ST, which
had been requested due to clinical presentation compat-
ible with CF and/or neonatal screening with altered im-
munoreactive trypsinogen values. Of these sweat samples,
29 (0.51 %) were excluded: (i) 23 showed sweat weight
lower than 75 mg; (ii) four had no indication about sweat
weight; (iii) one lacked laboratory data; (iv) one had no so-
dium value. Thus, 5,692 sweat samples were included in
this study. The gender of 17 subjects (0.3 %) could not be
determined, as the tests had been carried out with the
newborn’s mother’s name, after newborn screening. So,
3,023 sweat samples collected from males (53.3 %) and
2,652 (46.7 %) sweat samples collected from females were
included and analyzed.
The mean age of the subjects was 12.12 ± 17.84 years;
and median 4 (ranging from 0 to 85.58) years. In 146
(2.6 %) sweat samples, there was no record to confirm
the exact age at the time of the examination. The follow-
ing frequency was obtained for each age group: (i) ≤ 0 to
6 months: 634/5,611 (11.33 %) samples; (ii) > 6 months
to ≤ 18 years: 3,897/5,611 (69.5 %) samples; (iii) >
18 years: 1,080/5,611 (19.2 %) samples.
The mean sweat chloride concentration was 32.45 ±
27.67 mEq/L, median 22.30 (ranging from 1 to 213.10)
mEq/L. The mean sweat sodium level was 36.45 ±
21.56 mEq/L, median 29.5 (ranging from 6.30 to 154.70)
mEq/L. Clinical indications for having the sweat test per-
formed included (i) breathing symptoms: 2,920/3,791
(77 %); (ii) digestive symptoms: 464/3,791 (12.2 %); (iii)
nutritional symptoms: 435/3,791 (11.5 %); (iv) others:
467/3,791 (12.3 %). The initial medical request for ST of
1,901/5,692 (33.4 %) sweat samples could not be ob-
tained. The sweat chloride/sodium ratio showed a mean
level of 0.821 ± 0.250; median of 0.799 (ranging from
0.06 to 2.51).
Considering the quality of the ST based on the propor-
tion of sweat chloride and sweat sodium, the test was
performed correctly in 5,023/5,692 (88.2 %) samples,
and incorrectly in 669/5,692 (11.8 %).
The sweat samples were grouped into four reference
ranges for chloride and their respective interpretative
Fig. 1 Sweat test quality by the chloride sweat and sodium sweat (proposed criteria)
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comments: (i) chloride < 30 mEq/L: 3,651/5,692 (64.1 %);
(ii) chloride ≥ 30 mEq/L to < 40 mEq/L: 652/5,692 (11.5 %);
(iii) chloride ≥ 40 mEq/L to < 60 mEq/L: 673/5,692
(11.8 %); (iv) chloride ≥ 60 mEq/L: 716/5,692 (12.6 %).
In comparative analysis, there was no association be-
tween the quality of ST and: (i) symptoms to request the
test [breathing (p = 0.084), digestive (p = 0.753), nutri-
tional (p = 0.824) and others (p = 0.136)], and (ii) sweat
weight (p = 0.416). At the same time, there was a positive
association with: (i) gender (p = 0.001), (ii) result of ST
(p < 0.001), (iii) sweat chloride/sodium ratio (p < 0.001),
and (iv) subject’s age at the time of the ST [grouped by
category (p < 0.001) and numerical order (p < 0.001)]
(Table 1 and Fig. 2).
For the subset of 169 patients with CF and two CFTR
mutations Class I, II and/or III, in comparative analysis.
There was no association between the quality of ST and:
(i) gender (p = 1); (ii) subject’s age at the time of the ST
grouped by category (p = 0.128); (iii) symptoms to request
the test [breathing, digestive, nutritional and others – all
patients with CF showed corrected data (p > 0.05)], (iv)
sweat weight (p = 0.191), (v) sweat sodium values (p =
0.151). At the same time, there was a positive association
with: (i) sweat chloride/sodium ratio (p < 0.001), (ii) sweat
chloride values (p = 0.047), (iii) subject’s age at the time of
the ST grouped by numerical order (p = 0.001) (Table 2).
The frequency of CFTR mutations Class I, II and/or
III is showed in the Table 3.
Discussion
Patients with two identified mutations in the CFTR gene
do not usually show normal sweat values in their tests.
CF patients show proportionately elevated values for
both sodium and chloride electrolytes; with a difference
between them, that does not usually exceed 15 mEq/L.
In CF, sweat sodium concentration is usually lower than
sweat chloride concentration, and the opposite relation-
ship is observed in individuals without CF [18].
In this study, this parameter was used to assess the
quality of ST. When comparing the quality of ST with
gender, it was observed that the numbers of correct tests
were greater in males than females. A possible explanation
is the fact that women produce lower sweat volume due
to the constitution of their sweat glands. Men have fewer
active sweat glands, but higher sweating rate per gland.
Women show lower cholinergic and β-adrenergic sweat
secretion rates than men [8, 9].
The comparison between the quality and results of ST
for CF diagnosis showed a higher number of incorrect
tests in the chloride concentration range of 40 to
60 mEq/L, known as borderline range for the ST, as deter-
mined by Gibson and Cooke [14]. Some studies approach
the need to assess the test results with age-related refer-
ence intervals [1, 2, 11, 12, 19]. Patients with clinical CF
and chloride levels in ST between 30 and 59 mEq/L may
have two mutations in the CFTR gene [12, 20].
Sweat chloride reference value between 30 and
59 mEq/L is associated with borderline range, depending
on the individual’s age, and it may possibly include indi-
viduals with Transmembrane Conductance Regulator
Related Metabolic Syndrome. It is estimated that 8 to
15 % of subjects in this group may receive delayed diag-
nosis of CF and the initial clinical presentation of CF
may be confused with other respiratory diseases [21, 22].
Table 1 Comparison between the quality of the sweat test based on the concentrations of sweat chloride and sweat sodium
(proposed criteria) and the gender and age of subjects examined, as well as the results of the sweat test in view of the sweat
chloride concentration obtained in the exam
Variable Group Quality of Sweat Test by
Proposed Criteria
p-value ORcorrect 95 % CI ORincorrect 95 % CI
Correct Incorrect Total
Gender Male 2707 316 3023 0.001 1.311 1.115 to 1.541 0.763 0.649 to 0.897
Female 2300 352 2652 1 - 1 -
Total 5007 668 5675
Result of diagnosis of
cystic fibrosis
<30 mEq/L 3462 189 3651 < 0.001 5.633 4.711 to 6.734 0.178 0.148 to 0.212
≥ 30 to < 40 mEq/L 538 114 652 0.584 0.468 to 0.728 1.712 1.374 to 2.135
≥ 40 to < 60 mEq/L 471 202 673 0.239 0.198 to 0.289 4.180 3.456 to 5.057
≥ 60 mEq/L 552 164 716 0.380 0.312 to 0.463 2.630 2.160 to 3.203
Total 5023 669 5692
Subject’s age 0 to 6 months 598 36 634 < 0.001 2.312 1.634 to 3.27 0.433 0.306 to 0.612
> 6 months to≤ 18 years 3591 306 3897 2.883 2.44 to 3.405 0.347 0.294 to 0.410
> 18 years 778 302 1080 0.210 0.177 to 0.25 4.755 4.001 to 5.650
Total 4967 644 5611
OR odds ratio, CI confidence interval, % percentage, mEq/L milliequivalents per liter. Alpha = 0.05
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According to the Cystic Fibrosis Foundation, CF is
likely to be diagnosed when chloride concentration is
greater than or equal to 60 mEq/L in two-sample ST.
For infants up to six months of age, CF is very unlikely
to be diagnosed when the chloride concentration is
equal to or less than 29 mEq/L; as well as for individuals
older than six months of age, when chloride concentra-
tion is equal to or less than 39 mEq/L. In our study, a
greater number of incorrect tests were observed in the
age group over 18 years. It appears that sweat chloride
peaked in adults over 18 years of age, suggesting that the
borderline value of 60 mEq/L to diagnose CF may not
be sensitive for all age groups [2]. During the first 24 h
after birth, sweat electrolyte values may be transiently
elevated in normal infants, followed rapid decline of
electrolytes in the first days of life. Moreover, it can be
difficult to obtain adequate amount of sweat during the
first weeks after birth, especially in preterm infants [23].
The concentration of electrolytes in the sweat in-
creases with age and healthy adults may have chloride
levels above 60 mEq/L [24, 25]. Furthermore, at the time
of interpretation of ST, it should be considered that
some rare CFTR gene may be related to borderline or
negative values ST [18, 25].
Fig. 2 a and b Association between quality of sweat test (proposed criteria) and sweat chloride/sodium ratio. Correct: N = 5,023; mean = 0.784 ±
0.234; median = 0.766; range from 0.06 to 2.51; Incorrect: N = 669; mean = 1.102 ± 0.184; median = 1.071; range from 0.66 to 2.31. p < 0.001. c and
d Association between quality of the sweat test and the subject’s age at the time of the examination. Correct: N = 4912; mean = 10.545 ± 16.523;
median = 4; range from 0 to 85.58; Incorrect: N = 634; mean = 24.370 ± 22.366; median = 15.92; range 0 to 80.83. p < 0.001. Statistical analysis was
performed by Mann-Whitney test. α = 0.05
Table 2 Comparison between the quality of the sweat test based on the concentrations of sweat chloride and sweat sodium
(proposed criteria) and age of subjects examined, as well as the results of the sweat test in view of the sweat chloride concentration
obtained in the exam. All subjects had cystic fibrosis and two CFTR mutations Class I, II and/or III
Variable Group Number Mean ± SD Median Minimum Maximum p-value
Sweat chloride/sodium ratio Correct 155 1.33 ± 0.24 1.27 1 2.11 <0.001
Incorrect 4 0.94 ± 0.03 0.93 0.9 0.97
Sweat chloride values Correct 155 112.48 ± 19.70 111.61 63.70 159.20 0.047
Incorrect 4 93.34 ± 13.52 94.18 79.61 105.40
Subject’s age Correct 133 3.47 ± 5.53 1 0 37.33 0.001
Incorrect 2 24.13 ± 8.66 24.12 18 30.25
N number of patients, SD standard deviation, CFTR Cystic fibrosis transmembrane regulator. The statistical analysis was performed by the Mann-Whitney test. Alpha = 0.05
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In addition to CF, some diseases may cause increased
concentrations of sweat chloride, and most diseases can
be differentiated based on clinical presentations. Some
examples include: atopic dermatitis, hypogammaglobuli-
nemia, glycogen storage disease type I, mucopolysac-
charidosis type I, nephrogenic diabetes insipidus,
pseudohypoaldosteronism, celiac disease, adrenal insuffi-
ciency, and untreated hypothyroidism. False positive re-
sult may occur in case of malnutrition, dehydration, skin
conditions (eczema or rash) and ST technical errors dur-
ing induction, collection and measure of chloride and
sodium concentrations [18, 25].
False negative result is related to the presence of
edema, use of mineralocorticoid, collection and analysis
of insufficient amount of sweat, and other technical
problems [25, 26]. Sweat sample was collected by experi-
enced personnel in accordance with international guide-
lines and internal quality control procedures, in order to
minimize possible methodological errors and misdiag-
nosis, as some symptoms may resemble those of CF.
There were two limitations to this study. First, this
study did not include controls: all subjects were referred
to ST due to their clinical manifestations, positive
newborn screening results for CF, or family history. Sec-
ond, it was not possible to confirm a diagnosis of CF for
all patients using a genetic study. However, the data in-
cluding CFTR mutations was included in the present
manuscript and showed similar results as the first ana-
lysis for all exams performed.
Conclusions
It is assumed that quality of the ST can be assessed by
concentrations of sweat sodium and sweat chloride;
however, our study showed a great number of poor qual-
ity sweat tests. The quality of the tests was associated
with some important factors, such as gender, CF diag-
nostic results, and age of subjects. Although ST is con-
sidered the gold standard for the diagnosis of CF, it has
limitations and may produce both false positive and false
negative results. Constant efforts should be targeted to
understand ST results and seek quality markers to per-
form the tests, in order to allow accurate screening of
patients. The objective is to make identification of muta-
tions in the CFTR gene possible for all patients and/or
to make it a regular screening method for patients sus-
pected of having CF. The CFTR mutation screening can
Table 3 Distribution of patients with cystic fibrosis considering the genotype for mutations in the CFTR gene and classes of
identified mutations
Genotype Number Percent Group of patients
F508del/F508del 88a 52.1 Patients with two Class I, II and/or III
F508del/G542X 22 13
F508del/N1303K 8b 4.7
F508del/R1162X 8 4.7
F508del/R553X 5 3
F508del/1584-18672pbA > G 4 2.4
F508del/c.1717-1G > A 3 1.8
F508del/R1066C 4 2.4
3120 + 1G > A/R1066C 3 1.8
F508del/2183AA > G 1 0.6
F508del/ 6b-16 exon duplication 2 1.2
F508del/G85E 2 1.2
F508del/S549R (T > G) 2 1.2
F508del/S4X 3c 1.8
G542X/2183AA > G 1 0.6
G542X/R1162X 2 1.2
R1162X/R1162X 4 2.4
F508del/1812-1G > A 4 2.4
2183AA > G/2183AA > G 2 1.2
3120 + 1G > A/3120 + 1G > A 1 0.6
a 4 patients with cystic fibrosis and normal sweat chloride values were excluded (sweat chloride values: 13.10 mEq/L; 21,90 mEq/L; 35.70 mEq/L; 55.30 mEq/L); b 1
patient with cystic fibrosis and normal sweat chloride values in 5 sweat tests was excluded (sweat chloride values: 21.60 mEq/L; 23.44 mEq/L; 24.40 mEq/L;
29.50 mEq/L; 47 mEq/L); c 1 patient with cystic fibrosis and normal sweat chloride value was excluded (sweat chloride value: 52.40 mEq/L); N, Sample size; CFTR,
Cystic fibrosis transmembrane regulator
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only be achieved with minimized costs and improved
technical resources, which enable complete CFTR gene
sequencing, and include all mutations with their respect-
ive classes and types. Thus, considering the proportion
adopted in this study, the quantification and use of sweat
sodium is still needed in ST. Special attention should be
paid to borderline range for the diagnosis of CF, where a
greater chance of errors could be observed.
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